indazoles has been researched along with Response Evaluation Criteria in Solid Tumors in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Biswas, B; Chen, L; Chikatapu, C; Chung, HJ; Danchaivijitr, P; Erman, M; Hashem, T; Ingles, S; Kanesvaran, R; Karabulut, B; Lim, CS; Slimane, K; Wong, YF | 1 |
| Bernabeu, D; Blay, JY; Casali, PG; Collini, P; Cruz, J; de Alava, E; Diaz-Martin, J; Dopazo, J; Fernandez-Serra, A; Gonzalez-Aguilera, C; Grignani, G; Gutierrez, A; Hindi, N; Karanian, M; Le Cesne, A; Lopez-Guerrero, JA; Lopez-Pousa, A; Luna, P; Marcilla, D; Martin-Broto, J; Moura, DS; Peña-Chilet, M; Penel, N; Redondo, A; Stacchiotti, S | 1 |
| Ae, K; Ando, M; Ando, Y; Goto, T; Hamada, S; Hiraga, H; Kawai, A; Kobayashi, E; Kuwatsuka, Y; Matsumoto, Y; Naka, N; Nakayama, R; Nishida, Y; Ozaki, T; Takahashi, S; Tsuchiya, H; Ueda, T; Urakawa, H | 1 |
| Claps, M; Di Maio, M; Grassi, P; Guadalupi, V; Martinetti, A; Mennitto, A; Procopio, G; Raimondi, A; Sepe, P; Sottotetti, E; Stellato, M; Verzoni, E; Zattarin, E | 1 |
| Adamski, H; Battistella, M; Bertucci, F; Da Meda, L; Dalac, S; Delyon, J; Ghrieb, Z; Guillot, B; Jouary, T; Lebbe, C; Leccia, MT; Meyer, N; Mortier, L; Mourah, S; Pedeutour, F; Porcher, R; Vicaut, E | 1 |
| Choi, H; Gupta, S; Kang, HC; Lu, L; Matrana, MR; Tannir, NM; Wei, W | 1 |
| Bao, F; Christiansen, J; Foley, P; Hornby, Z; Luo, D; Maneval, EC; Multani, P; Sigal, D; Tartar, M; Xavier, M | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Miyake, M; Narita, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, A | 1 |
| Dietrich, M; Grünwald, V; Pond, GR | 1 |
| Anurova, O; Asano, N; Ben-Ami, E; Benjamin, RS; Blay, JY; Boye, K; Brahmi, M; Broto, JM; Brunello, A; Casali, PG; Collini, P; Dei Tos, AP; Desar, IME; Fedenko, A; Flucke, U; Frezza, AM; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Hornick, JL; Jones, RL; Kawai, A; Lo Vullo, S; Lobmaier, I; Lucibello, F; Mariani, L; Mir, O; Palmerini, E; Philippe, T; Picci, P; Ranchere, D; Ratan, R; Renne, SL; Rutkowski, P; Sbaraglia, M; Stacchiotti, S; Teterycz, P; Thway, K; Vincenzi, B; Wagner, AJ; Wagrodzki, M; Wang, WL; Yoshida, A | 1 |
| Basso, U; Bearz, A; Berruti, A; Bracarda, S; Buti, S; Cartenì, G; Caserta, C; Cognetti, F; Cortesi, E; De Giorgi, U; Fornarini, G; Galli, L; Giannarelli, D; Lo Re, G; Pignata, S; Porta, C; Procopio, G; Rastelli, F; Sabbatini, R; Sternberg, CN; Turci, D | 1 |
| Bernabeu, D; Biscuola, M; Blay, JY; Casali, PG; Collini, P; Cruz, J; de Alava, E; Dei Tos, AP; Diaz-Martin, J; Dopazo, J; Dumont, S; Garcia Del Muro, X; Grignani, G; Gutierrez, A; Hindi, N; Italiano, A; LeCesne, A; Lopez-Pousa, A; Martin-Broto, J; Martinez-Trufero, J; Moura, DS; Palmerini, E; Peña-Chilet, M; Ranchere-Vince, D; Redondo, A; Sebio, A; Stacchiotti, S; Taron, M | 1 |
| Christian, S; Danciu, OC; Dudek, AZ; Fischer, JH; Liu, LC; Russell, MJ; Shah, HA; Venepalli, NK; Zacny, JP | 1 |
| Brown, P; Carducci, M; Hurwitz, H; Pili, R | 1 |
| Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
| Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T | 1 |
| Ali, SM; Amini, B; Elvin, JA; Erlich, RL; Gowen, K; Holmes, O; Meric-Bernstam, F; Miller, V; Piha-Paul, S; Ross, JS; Schrock, AB; Spritz, D; Stephens, PJ; Stockman, DL; Subbiah, V; Suh, JH; Vergilio, JA; Wang, WL; Zarzour, M; Zinner, R | 1 |
| Bedke, J; Stühler, V | 1 |
8 trial(s) available for indazoles and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Asia; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Middle East; Progression-Free Survival; Prospective Studies; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2021 |
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.
Topics: Aged; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Solitary Fibrous Tumors; Sulfonamides; Survival Rate | 2020 |
Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Neoplasm Grading; Neurofibrosarcoma; Neutropenia; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Sulfonamides; Young Adult | 2021 |
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans.
Topics: Adult; Aged; Biomarkers, Tumor; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Skin; Skin Neoplasms; Sulfonamides; Tumor Burden | 2021 |
Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Regression Analysis; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib; Treatment Outcome; Tumor Burden | 2018 |
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Humans; Indazoles; Male; Middle Aged; Multivariate Analysis; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Sulfonamides; Survival Analysis | 2019 |
Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors.
Topics: Adult; Age Factors; Aged; Azepines; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Patient Safety; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Assessment; Sex Factors; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Carbazoles; Cell Line; Endothelial Cells; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Swine; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
11 other study(ies) available for indazoles and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemokine CXCL12; Disease Progression; Drug Resistance, Neoplasm; E-Selectin; Female; Hepatocyte Growth Factor; Humans; Indazoles; Interleukin-6; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Osteopontin; Progression-Free Survival; Prospective Studies; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Survival Rate; Translational Research, Biomedical; Vascular Endothelial Growth Factor A | 2020 |
Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Salvage Therapy; Sulfonamides; Tomography, X-Ray Computed | 2017 |
Activity of Entrectinib in a Patient With the First Reported
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drugs, Investigational; Exons; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Intestinal Neoplasms; Intestine, Small; Low Back Pain; Male; Neoplasm Grading; Neuroendocrine Tumors; Oncogene Proteins, Fusion; Palliative Care; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiotherapy; Response Evaluation Criteria in Solid Tumors; Sequence Analysis, RNA; Treatment Outcome | 2017 |
Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Treatment Outcome | 2018 |
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrimidines; Remission Induction; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sarcoma; Sulfonamides; Young Adult | 2018 |
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retreatment; Sulfonamides; Sunitinib; Survival Rate | 2019 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2015 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors | 2017 |
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
Topics: Adolescent; Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Crizotinib; Female; Humans; Indazoles; Intestinal Neoplasms; Liver Neoplasms; Male; Middle Aged; Neuroectodermal Tumors; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Vascular Endothelial Growth Factor A; Young Adult | 2016 |
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Genetic Heterogeneity; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pharmacogenomic Testing; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib | 2016 |